Revenue increases for the firm's for high-throughput genomics and mass cytometry products were offset by declines in single-cell genomics product sales.
Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.
The system can measure dozens of markers at the single-cell level and, one researcher said, could aid studies of cellular heterogeneity in diseases like cancer.
The company gains global distribution rights for the Zurich team's histoCAT cytometry imaging software, which it will sell alongside its newly-launched Hyperion Imaging System.
Under the terms of the deal, Fluidigm has the right to commercialize the CFTR sample prep assay for research use on its Juno automated microfluidic system.
The company announced this week the sale of 9,090,909 shares of common stock, which it expects will raise proceeds of roughly $30 million before expenses.
Revenues for the quarter were $23.9 million compared to $28.2 million the year before, driven largely by a decline in the company's genomics business.
Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.
The South San Francisco, California-based single-cell biology firm brought in $25.5 million compared to $29.0 million in the first quarter of 2016.
Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.
A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.
A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.
Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.
In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.